Overcoming drug resistance to receptor tyrosine kinase inhibitors: Learning from lung cancer

Michihiko Kuwano, Kahori Sonoda, Yuichi Murakami, Kosuke Watari, Mayumi Ono

研究成果: ジャーナルへの寄稿評論記事

37 引用 (Scopus)

抄録

There are various receptor tyrosine kinase (TK)-targeted drugs that are currently used in the treatment of patients with non-small cell lung cancer (NSCLC). Among them, the epidermal growth factor receptor (EGFR) TK inhibitors (TKIs) are the most extensively studied. Receptor TKIs including EGFR TKIs have shown dramatic therapeutic efficacies in malignant tumors, which harbor activating mutations in the EGFR gene. However, within 1 or 2 years after treatment, patients harboring these mutations often develop resistance to TKI therapy. This review article is aimed at drawing attention to the fact that we must firunderstand how receptor TKI resistance is acquired to develop strategies for overcoming resistance to TKIs. Furthermore, an insight into the specific molecules or signaling pathways that mediate resistance is a key factor for understanding and overcoming acquired drug resistance. Finally, we present our views on the continuing battle against "drug resistance," and provide further guidelines and strategies on how to minimize the development of drug-resistant tumors.

元の言語英語
ページ(範囲)97-110
ページ数14
ジャーナルPharmacology and Therapeutics
161
DOI
出版物ステータス出版済み - 5 2016

Fingerprint

Receptor Protein-Tyrosine Kinases
Drug Resistance
Lung Neoplasms
Learning
Epidermal Growth Factor Receptor
erbB-1 Genes
Mutation
Therapeutics
Non-Small Cell Lung Carcinoma
Pharmaceutical Preparations
Protein-Tyrosine Kinases
Neoplasms
Guidelines

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmacology (medical)

これを引用

Overcoming drug resistance to receptor tyrosine kinase inhibitors : Learning from lung cancer. / Kuwano, Michihiko; Sonoda, Kahori; Murakami, Yuichi; Watari, Kosuke; Ono, Mayumi.

:: Pharmacology and Therapeutics, 巻 161, 05.2016, p. 97-110.

研究成果: ジャーナルへの寄稿評論記事

Kuwano, Michihiko ; Sonoda, Kahori ; Murakami, Yuichi ; Watari, Kosuke ; Ono, Mayumi. / Overcoming drug resistance to receptor tyrosine kinase inhibitors : Learning from lung cancer. :: Pharmacology and Therapeutics. 2016 ; 巻 161. pp. 97-110.
@article{0f9e0b1093064109872852c2c9ad903e,
title = "Overcoming drug resistance to receptor tyrosine kinase inhibitors: Learning from lung cancer",
abstract = "There are various receptor tyrosine kinase (TK)-targeted drugs that are currently used in the treatment of patients with non-small cell lung cancer (NSCLC). Among them, the epidermal growth factor receptor (EGFR) TK inhibitors (TKIs) are the most extensively studied. Receptor TKIs including EGFR TKIs have shown dramatic therapeutic efficacies in malignant tumors, which harbor activating mutations in the EGFR gene. However, within 1 or 2 years after treatment, patients harboring these mutations often develop resistance to TKI therapy. This review article is aimed at drawing attention to the fact that we must firunderstand how receptor TKI resistance is acquired to develop strategies for overcoming resistance to TKIs. Furthermore, an insight into the specific molecules or signaling pathways that mediate resistance is a key factor for understanding and overcoming acquired drug resistance. Finally, we present our views on the continuing battle against {"}drug resistance,{"} and provide further guidelines and strategies on how to minimize the development of drug-resistant tumors.",
author = "Michihiko Kuwano and Kahori Sonoda and Yuichi Murakami and Kosuke Watari and Mayumi Ono",
year = "2016",
month = "5",
doi = "10.1016/j.pharmthera.2016.03.002",
language = "English",
volume = "161",
pages = "97--110",
journal = "Pharmacology and Therapeutics",
issn = "0163-7258",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Overcoming drug resistance to receptor tyrosine kinase inhibitors

T2 - Learning from lung cancer

AU - Kuwano, Michihiko

AU - Sonoda, Kahori

AU - Murakami, Yuichi

AU - Watari, Kosuke

AU - Ono, Mayumi

PY - 2016/5

Y1 - 2016/5

N2 - There are various receptor tyrosine kinase (TK)-targeted drugs that are currently used in the treatment of patients with non-small cell lung cancer (NSCLC). Among them, the epidermal growth factor receptor (EGFR) TK inhibitors (TKIs) are the most extensively studied. Receptor TKIs including EGFR TKIs have shown dramatic therapeutic efficacies in malignant tumors, which harbor activating mutations in the EGFR gene. However, within 1 or 2 years after treatment, patients harboring these mutations often develop resistance to TKI therapy. This review article is aimed at drawing attention to the fact that we must firunderstand how receptor TKI resistance is acquired to develop strategies for overcoming resistance to TKIs. Furthermore, an insight into the specific molecules or signaling pathways that mediate resistance is a key factor for understanding and overcoming acquired drug resistance. Finally, we present our views on the continuing battle against "drug resistance," and provide further guidelines and strategies on how to minimize the development of drug-resistant tumors.

AB - There are various receptor tyrosine kinase (TK)-targeted drugs that are currently used in the treatment of patients with non-small cell lung cancer (NSCLC). Among them, the epidermal growth factor receptor (EGFR) TK inhibitors (TKIs) are the most extensively studied. Receptor TKIs including EGFR TKIs have shown dramatic therapeutic efficacies in malignant tumors, which harbor activating mutations in the EGFR gene. However, within 1 or 2 years after treatment, patients harboring these mutations often develop resistance to TKI therapy. This review article is aimed at drawing attention to the fact that we must firunderstand how receptor TKI resistance is acquired to develop strategies for overcoming resistance to TKIs. Furthermore, an insight into the specific molecules or signaling pathways that mediate resistance is a key factor for understanding and overcoming acquired drug resistance. Finally, we present our views on the continuing battle against "drug resistance," and provide further guidelines and strategies on how to minimize the development of drug-resistant tumors.

UR - http://www.scopus.com/inward/record.url?scp=84961891781&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84961891781&partnerID=8YFLogxK

U2 - 10.1016/j.pharmthera.2016.03.002

DO - 10.1016/j.pharmthera.2016.03.002

M3 - Review article

C2 - 27000770

AN - SCOPUS:84961891781

VL - 161

SP - 97

EP - 110

JO - Pharmacology and Therapeutics

JF - Pharmacology and Therapeutics

SN - 0163-7258

ER -